| Literature DB >> 33804069 |
Babak Saravi1,2, Zhen Li1, Corinna N Lang3,4, Bonaventura Schmid5, Frauke K Lang6, Sibylle Grad1, Mauro Alini1, Robert Geoffrey Richards1, Hagen Schmal2,7, Norbert Südkamp2, Gernot M Lang2.
Abstract
Evidence has arisen in recent years suggesting that a tissue renin-angiotensin system (tRAS) is involved in the progression of various human diseases. This system contains two regulatory pathways: a pathological pro-inflammatory pathway containing the Angiotensin Converting Enzyme (ACE)/Angiotensin II (AngII)/Angiotensin II receptor type 1 (AGTR1) axis and a protective anti-inflammatory pathway involving the Angiotensin II receptor type 2 (AGTR2)/ACE2/Ang1-7/MasReceptor axis. Numerous studies reported the positive effects of pathologic tRAS pathway inhibition and protective tRAS pathway stimulation on the treatment of cardiovascular, inflammatory, and autoimmune disease and the progression of neuropathic pain. Cell senescence and aging are known to be related to RAS pathways. Further, this system directly interacts with SARS-CoV 2 and seems to be an important target of interest in the COVID-19 pandemic. This review focuses on the involvement of tRAS in the progression of the mentioned diseases from an interdisciplinary clinical perspective and highlights therapeutic strategies that might be of major clinical importance in the future.Entities:
Keywords: COVID-19; RAS; cardiovascular; inflammation; intervertebral disc; regeneration; renin-angiotensin; senescence; vulvodynia
Year: 2021 PMID： 33804069 PMCID： PMC7999456 DOI： 10.3390/cells10030650
Source DB: PubMed Journal: Cells ISSN： 2073-4409 Impact factor: 6.600